A fascinating look into the calculated world of drug development! Smart biotech firms frequently choose a strategic pivot: tackling second-line or later treatment settings *before* going head-to-head with the established first-line standard of care. Why? It dramatically lowers the burden of proof required for success. This approach offers a clearer, more attainable path to market entry for promising therapies. See the rationale behind this strategic playbook! #Biotech #PharmaStrategy #InvestmentTips #DrugDevelopment #ScienceTok - @dansfera